|
1
|
Hanahan D and Coussens ML: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nisticò P and Ciliberto G: Biological
mechanisms linked to inflammation in cancer: Discovery of tumor
microenvironment-related biomarkers and their clinical application
in solid tumors. Int J Biol Markers. 35 (Suppl 1):S8–S11.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sfanos KS, Yegnasubramanian S, Nelson WG
and De Marzo AM: The inflammatory microenvironment and microbiome
in prostate cancer development. Nat Rev Urol. 15:11–24.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tang T, Huang X, Gang Z, Zhengtao H, Xueli
B and Tingbo L: Advantages of targeting the tumor immune
microenvironment over blocking immune checkpoint in cancer
immunotherapy. Signal Transduct Target Ther. 6(72)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baghban R, Roshangar L, Jahanban-Esfahlan
R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T and
Zare P: Tumor microenvironment complexity and therapeutic
implications at a glance. Cell Commun Signal. 18(59)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bahmad HF, Jalloul M, Azar J, Moubarak MM,
Samad TA, Mukherji D, Al-Sayegh M and Abou-Kheir W: Tumor
microenvironment in prostate cancer: Toward identification of novel
molecular biomarkers for diagnosis, prognosis, and therapy
development. Front Genet. 12(652747)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Archer M, Dogra N and Kyprianou N:
Inflammation as a driver of prostate cancer metastasis and
therapeutic resistance. Cancers (Basel). 12(2984)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Barthes J, Özçelik H, Hindié M,
Ndreu-Halili A, Hasan A and Vrana NE: Cell microenvironment
engineering and monitoring for tissue engineering and regenerative
medicine: The recent advances. Biomed Res Int.
2014(921905)2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Emami Nejad A, Najafgholian S, Rostami A,
Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy
Javanmard S, Taherian M, Ahmadlou M, et al: The role of hypoxia in
the tumor microenvironment and development of cancer stem cell: A
novel approach to developing treatment. Cancer Cell Int.
21(62)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jang JH, Kim DH and Surh YJ: Dynamic roles
of inflammasomes in inflammatory tumor microenvironment. NPJ Precis
Oncol. 5(18)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang E, Wang X, Gong Z, Yu M, Wu H and
Zhang D: Exosome-mediated metabolic reprogramming: The emerging
role in tumor microenvironment remodeling and its influence on
cancer progression. Signal Transduct Target Ther.
5(242)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Riemann A, Reime S and Thews O: Acidic
extracellular environment affects miRNA expression in tumors in
vitro and in vivo. Int J Cancer. 144:1609–1618. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ene CD, Penescu MN, Georgescu SR, Tampa M
and Nicolae I: Posttranslational modifications pattern in clear
cell renal cell carcinoma. Metabolites. 11(10)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nicolae I, Nicolae CD, Schipor S and
Caragheorgheopol A: Influence of iron deficiency on angiogenesis in
melanoma patients. Endocr Abstr. 32(P547)2013.
|
|
15
|
Schipor S, Caragheorgheopol A, Nicolae CD,
Nicolae I and Paun D: Serum levels of VEGF in cutaneous melanoma.
Clin Chem Lab Med. 49 (Suppl):S1–S874. 2011.
|
|
16
|
Pavlakis D, Kampantais S, Gkagkalidis K,
Gourvas V, Memmos D, Tsionga A, Dimitriadis G and Vakalopoulos I:
Hypoxia-inducible factor 2a expression is positively correlated
with gleason score in prostate cancer. Technol Cancer Res Treat.
20(1533033821990010)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lekas A, Lazaris AC, Deliveliotis C,
Chrisofos M, Zoubouli C, Lapas D, Papathomas T, Fokitis I and
Nakopoulou L: The expression of hypoxia-inducible factor-1alpha
(HIF-1alpha) and angiogenesis markers in hyperplastic and malignant
prostate tissue. Anticancer Res. 26:2989–2993. 2006.PubMed/NCBI
|
|
18
|
Binder MJ and Ward AC: The role of the
metzincin superfamily in prostate cancer progression: A
systematic-like review. Int J Mol Sci. 22(3608)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li S, van Dijk CGM, Meeldijk J, Kok HM,
Blommestein I, Verbakel ALF, Kotte M, Broekhuizen R, Laclé MM,
Goldschmeding R, et al: Extracellular granzyme K modulates
angiogenesis by regulating soluble VEGFR1 release from endothelial
cells. Front Oncol. 11(681967)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ceci C, Atzori MG, Lacal PM and Graziani
G: Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating
tumor invasion: Experimental evidence in different metastatic
cancer models. Int J Mol Sci. 21(1388)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Failla CM, Carbo M and Morea V: Positive
and negative regulation of angiogenesis by soluble vascular
endothelial growth factor receptor-1. Int J Mol Sci.
19(1306)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Geng JH, Lin VC, Yu CC, Huang CY, Yin HL,
Chang TY, Lu TL, Huang SP and Bao BY: Inherited variants in Wnt
pathway genes influence outcomes of prostate cancer patients
receiving androgen deprivation therapy. Int J Mol Sci.
17(1970)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Soulitzis N, Karyotis I, Delakas D and
Spandidos DA: Expression analysis of peptide growth factors VEGF,
FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic
hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
|
|
24
|
Ene CD, Nicolae I, Ene C, Tampa M, Matei C
and Georgescu SR: Effect of tobacco alkaloids on the endocrine
system. Rev Chim. 66:628–633. 2015.
|
|
25
|
Matsuoka Y, Nakayama H, Yoshida R, Hirosue
A, Nagata M, Tanaka T, Kawahara K, Sakata J, Arita H, Nakashima H,
et al: IL-6 controls resistance to radiation by suppressing
oxidative stress via the Nrf2-antioxidant pathway in oral squamous
cell carcinoma. Br J Cancer. 115:1234–1244. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ene CD, Tampa M, Nicolae I, Mitran CI,
Mitran MI, Matei C, Caruntu A, Caruntu C and Georgescu SR:
Antiganglioside antibodies and inflammatory response in cutaneous
melanoma. J Immunol Res. 2020(2491265)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Anghel AE, Ene CD, Nicolae I, Budu VA,
Constantin C and Neagu M: Interleukin 8-major player in cutaneous
melanoma metastasic process. Rom Biotechnol Lett. 20:10911–10920.
2015.
|
|
28
|
Ene CD and Nicolae I: Gangliosides and
antigangliosides in malignant melanoma. Melanoma-chapter 14,
361-401. Current Clinical Management and Future Therapeutics; Murph
M (ed). InTech: London, UK, 2015.
|
|
29
|
Ene CD, Anghel AE, Neagu M and Nicolae I:
25-OH vitamin D and interleukin-8: Emerging biomarkers in cutaneous
melanoma development and progression. Mediators Inflamm.
2015(904876)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cheteh EH, Sarne V, Ceder S, Bianchi J,
Augsten M, Rundqvist H, Egevad L, Östman A and Wiman KG:
Interleukin-6 derived from cancer-associated fibroblasts attenuates
the p53 response to doxorubicin in prostate cancer cells. Cell
Death Discov. 6(42)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Culig Z: Response to androgens and
androgen receptor antagonists in the presence of cytokines in
prostate cancer. Cancers (Basel). 13(2944)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tran MGB, Bibby BAS, Yang L, Lo F, Warren
AY, Shukla D, Osborne M, Hadfield J, Carroll T, Stark R, et al:
Independence of HIF1a and androgen signaling pathways in prostate
cancer. BMC Cancer. 20(469)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Huang M, Du H, Zhang L, Che H and Liang C:
The association of HIF-1α expression with clinicopathological
significance in prostate cancer: A meta-analysis. Cancer Manag Res.
10:2809–2816. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Teishima J, Hayashi T, Nagamatsu H, Shoji
K, Shikuma H, Yamanaka R, Sekino Y, Goto K, Inoue S and Matsubara
A: Fibroblast growth factor family in the progression of prostate
cancer. J Clin Med. 8(183)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rivera-Pérez J, Monter-Vera MDR,
Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T and
Flores-Estrada J: Evaluation of VEGF and PEDF in prostate cancer: A
preliminary study in serum and biopsies. Oncol Lett. 15:1072–1078.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ene CV, Nicolae I, Geavlete B, Geavlete P
and Ene CD: IL-6 signaling link between inflammatory tumor
microenvironment and prostatic tumorigenesis. Anal Cell Pathol
(Amst). 2022(5980387)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Melegh Z and Oltean S: Targeting
angiogenesis in prostate cancer. Int J Mol Sci.
20(2676)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ioannidou E, Moschetta M, Shah S, Parker
JS, Ozturk MA, Pappas-Gogos G, Sheriff M, Rassy E and Boussios S:
Angiogenesis and anti-angiogenic treatment in prostate cancer:
mechanisms of action and molecular targets. Int J Mol Sci.
22(9926)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Franko A, Berti L, Hennenlotter J, Rausch
S, Scharpf MO, de Angelis MH, Stenzl A, Peter A, Birkenfeld AL,
Lutz SZ, et al: Increased expressions of matrix metalloproteinases
(MMPs) in prostate cancer tissues of men with type 2 diabetes.
Biomedicines. 8(507)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gong Y, Chippada-Venkata UD and Oh WK:
Roles of matrix metalloproteinases and their natural inhibitors in
prostate cancer progression. Cancers (Basel). 6:1298–1327.
2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dinu L, Ene CD, Nicolae I, Tampa M, Matei
C and Georgescu SR: Serum levels of 8-hydroxy-deoxyguanosine under
the chemicals influence. Rev Chim. 65:1319–1326. 2014.
|
|
42
|
Quintero-Fabián S, Arreola R,
Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V,
Lara-Riegos J, Ramírez-Camacho MA and Alvarez-Sánchez ME: Role of
matrix metalloproteinases in angiogenesis and cancer. Front Oncol.
9(1370)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Nicolae CD, Coman OA, Ene C, Nicolae I and
Fulga I: Hepcidin in neoplastic disease. J Med Life. 69:365–360.
2013.PubMed/NCBI
|
|
44
|
Ikeda T, Sun L, Tsuruoka N, Ishigaki Y,
Yoshitomi Y, Yoshitake Y and Yonekura H: Hypoxia down-regulates
sFlt-1 (sVEGFR-1) expression in human microvascular endothelial
cells by a mechanism involving mRNA alternative processing. Biochem
J. 436:399–407. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Persu C, Braschi E and Lavelle J: A review
of prospective clinical trials for neurogenic bladder:
Pharmaceuticals. Cent European J Urol. 67:264–269. 2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Macagno A, Athanasiou A, Wittig A, Huber
R, Weber S, Keller T, Rhiel M, Golding B and Schiess R: Analytical
performance of thrombospondin-1 and cathepsin D immunoassays part
of a novel CE-IVD marked test as an aid in the diagnosis of
prostate cancer. PLoS One. 15(e0233442)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kaur S, Bronson SM, Pal-Nath D, Miller TW,
Soto-Pantoja DR and Roberts DD: Functions of thrombospondin-1 in
the tumor microenvironment. Int J Mol Sci. 22(4570)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Vacaroiu IA, Cuiban E, Geavlete BG,
Gheorghita V, David C, Ene CE, Bulai C, Lupusoru GE, Lupusoru M,
Balcangiu-Stroescu AE, et al: Chronic kidney disease-an
underestimated risk factor for antimicrobial resistance in patients
with urinary tract infections. Biomedicines.
10(2368)2022.PubMed/NCBI View Article : Google Scholar
|
